Pharmaceutical companies which increase prices of their medicines beyond 10 per cent in a year will face regulatory action.
The resultant price increase was the cause of a surprise upward variation in the "drug and medicines" segment of the weekly wholesale price index of the ministry of commerce and Industry last week, it is learnt.
Reliance, Bharti's response to Ahmedabad's space crunch.
With the bidding for the generics business of Merck set to begin from Monday, domestic pharmaceutical companies in the fray, Ranbaxy Laboratories and Dr Reddy's Laboratories, are unlikely to go for an all-out bidding war.
The decision has come in the wake of allegations of plagiarism against the Mashelkar panel report.
"The product technology is coming from DNDi. Cipla will manufacture and make the product available in southeast Asia and other parts of the world at affordable pre-agreed prices," Amar Lulla, joint managing director, Cipla, said.
The international health organisations, protesting against Swiss pharmaceutical major Novartis AG's legal challenge to provisions of the Indian Patent Act
Even as the domestic pharmaceutical industry is exploring new markets in Latin America and the Commonwealth of Independent States, exports to countries in Africa are declining.
Congress President Sonia Gandhi has pulled up the central government for slow implementation of the UPA's 20-point programme, sources in the government say.
Having cut eight deals last year, the $1.3 billion pharma major Ranbaxy probably has the sharpest negotiating skills in the business.
The government is expected to shortly classify the entire food products industry into three clearly defined categories, for licensing as well as taxation purposes.
Annual plan of 65 ministries and depts hiked 27%.
Ministry to amend Act to bring all oral, skin and hair care products under its purview.
Ranbaxy Laboratories, the biggest member of the Indian Pharmaceutical Alliance, has come out in the open against the alliance's stand on patent issues.
The Mashelkar panel's recommendation to consider all modifications and variants of new chemical entities (NCEs) as patentable has invited criticism from sections of Indian pharmaceutical industry and public interest organisations
The domestic pharmaceutical industry and non-government organisations are up in arms against the first ever Indo-US tie-up on intellectual property rights
The finance ministry is expected to announce a life insurance package for below poverty line workers in the unorganised sector in the forthcoming Union Budget.
The finance ministry is expected to announce a life insurance package for below poverty line workers in the unorganised sector in the forthcoming Union Budget.
Under the banner of the CII, domestic drug majors have approached Cabinet Secretary BK Chaturvedi for being allowed to present their views on the new pharmaceutical policy, scheduled to be discussed by the Union Cabinet on Thursday.
The corporate healthcare segment may replicate the success of the Indian IT sector, say experts.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances